Rimexolone. A review of its pharmacological properties and clinical potential in the management of ocular inflammation

BioDrugs

Volumn 8, Issue 1, 1997, Pages 68-79

  Brogden, Rex N ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; DEXAMETHASONE; GLUCOCORTICOID; PLACEBO; PREDNISOLONE; PREDNISOLONE ACETATE; RIMEXOLONE;

ALLERGIC CONJUNCTIVITIS; ANTIINFLAMMATORY ACTIVITY; CATARACT EXTRACTION; CLINICAL TRIAL; CORNEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; EYE INFLAMMATION; EYE IRRITATION; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; SKIN; SUSPENSION; UVEITIS; VISUAL IMPAIRMENT;

EID: 0030843859     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708010-00008     Document Type: Review

References (28)

1. Fox PK, Lewis AJ, Rae RM, et al. The biological properties of Org 6216, a new type of steroid with a selective local anti-inflammatory action. Arzneimittelforschung 1980; 30: 55-9
2. Lewis AJ, Fox PK. Org 6216: a novel type of anti-inflammatory steroid [proceedings]. J Pharm Pharmacol 1976 Dec; 28 Suppl.: 82P
3. Hackett RB. Expert report on the the pharmaco-toxocological documentation of rimexolone ophthalmic suspension 1.0%. Alcon Laboratories Inc, Fort Worth, Texas, USA; Sep 1996
4. Abelson M, George M, Drake M, et al. Evaluation of rimexolone ophthalmic suspension in the antigen challenge model of allergic conjunctivitis [abstract 2094-21]. Invest Ophthalmol Vis Sci 1992; 33 Suppl.: 1112
5. Expert Opinion Report on rimexolone 1% ophthalmic suspension:postoperative ocular inflammation studies. Alcon Laboratories Limited, Fort Worth, Texas, USA; Jun 1994
6. Hara T. Effect of topical application of hydrocortisone on the corneal thickness. Exp Eye Res 1970; 10: 302-12
7. Baum JL, Levene RZ. Corneal thickness after topical corticosteroid therapy. Arch Ophthalmol 1968 Apr; 79: 366-9
8. Expert opinion report on rimexolone 1% ophthalmic suspension. Alcon Laboratories Inc, Fort Worth, Texas; Jul 3 1996
9. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol 1963; 70: 106-13
10. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. 1. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963; 70: 482-91
11. Leibowitz HM, Bartlett JD, Rich R, et al. Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol 1996 Aug; 114: 933-7
12. Balfour JA, Benfield P. Rimexolone. Biodrugs 1997 Feb; 7: 158-63
13. Foster CS, Alter G, Debarge LR, et al. Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996 Aug; 122: 171-82
14. Miami Study Group. Cystoid macular edema in aphakic and pseudophakic eyes. Am J Ophthalmol 1979; 88: 45-8
15. King DG, Layden WE. Glaucoma and intraocular lens implantation. In: Ritch R, Shields B, Krupin T, editors. The glaucomas. New York: CV Mosby Co, 1989: 1285-97
16. Assil KK, Massry G, Lehmann R, et al. Control of ocular inflammation following cataract extraction with rimexolone 1% ophthalmic suspension: a prospective, randomised multicenter study. 1996 (Data on file)
17. Bron A, Solé P, Raspiller A, et al. A comparison of rimexolone 1% and dexamethasone 0.1% eye drops in control of post-cataract surgery inflammation. A double-masked pilot study. Alcon Laboratories Limited, Fort Worth, Texas, USA, 1996
18. Assil KK, Baca-Lozada O, Cruz A, et al. Comparison of rimexolone 1% ophthalmic suspension to prednisolone acetate 1% in control of post-cataract surgery inflammation [abstract 2423-B113]. Invest Ophthalmol Vis Sci 1997; 38 (4) Suppl.: 524
19. Ciprandi G, Buscaglia S, Cerqueti PM, et al. Drug treatment of allergic conjunctivitis: a review of the evidence. Drugs 1992 Feb; 43: 154-76
20. Vandewalker ML, Lentz KJ, Caine R, et al. 1.0% rimexolone ophthalmic suspension (ROS) vs placebo in patients with seasonal allergic conjunctivitis (SAC) [abstract no. 35]. Abstract book: 1994 Annual Meeting. American College of Allergy & Immunology; Nov 5-9, 1994; San Francisco: 9
21. Clark AF. Steroids, ocular hypertension, and glaucoma. J Glaucoma 1995; 4 (5): 354-69
22. Leibowitz HM, Kupferman A. Anti-inflammatory medications. Int Ophthalmol Clin 1980; 20: 117-34
23. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. Invest Ophthalmol Vis Sci 1965; 4: 187-97
24. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol Vis Sci 1965; 4: 198-205
25. Anglade E, Whitcup SM. The diagnosis and management of uveitis. Drugs 1995 Feb; 49: 213-23
26. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham eye study monograph. An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980 May-Jun; 24 Suppl.: 335-405
27. Dawson CR, Schwab IR. Epidemiology of cataract - a major cause of preventable blindness. Bull World Health Organ 1981; 59: 493-501
28. Ciprandi G, Buscaglia S, Canonica GW. Management of allergic conjunctivitis. Clin Immunother 1996 May; 5: 374-91